Off-the-shelf CAR-T cell therapies for relapsed or refractory B-cell malignancies: latest update from ASH 2023 annual meeting
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Off-the-shelf CAR-T cell therapies for relapsed or refractory B-cell malignancies: latest update from ASH 2023 annual meeting ; volume:17 ; number:1 ; day:6 ; month:5 ; year:2024 ; pages:1-7 ; date:12.2024
Journal of hematology & oncology ; 17, Heft 1 (6.5.2024), 1-7, 12.2024
- Urheber
-
Kang, Yun
Li, Chenggong
Mei, Heng
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13045-024-01550-9
- URN
-
urn:nbn:de:101:1-2407152122216.384399645944
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:52 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kang, Yun
- Li, Chenggong
- Mei, Heng
- SpringerLink (Online service)
Ähnliche Objekte (12)
An “off-the-shelf” CD2 universal CAR-T therapy for T-cell malignancies
BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting
Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma
Allogeneic stem cell transplantation combined with conditioning regimen including donor-derived CAR-T cells for refractory/relapsed B-cell lymphoma
Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting
Engineering CAR-T cells
Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma
Current approaches to develop “off-the-shelf” chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review
Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopietic stem cell transplantation
A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress
An “off-the-shelf” CD2 universal CAR-T therapy for T-cell malignancies
BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting
Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma
Allogeneic stem cell transplantation combined with conditioning regimen including donor-derived CAR-T cells for refractory/relapsed B-cell lymphoma
Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting
Engineering CAR-T cells
Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma
Current approaches to develop “off-the-shelf” chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review
Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopietic stem cell transplantation
A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress
An “off-the-shelf” CD2 universal CAR-T therapy for T-cell malignancies
BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting
Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma
Allogeneic stem cell transplantation combined with conditioning regimen including donor-derived CAR-T cells for refractory/relapsed B-cell lymphoma
Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting
Engineering CAR-T cells
Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma
Current approaches to develop “off-the-shelf” chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review
Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopietic stem cell transplantation
A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma